A2RL
25.7.2024 08:31:32 CEST | Business Wire | Press release
The Abu Dhabi Autonomous Racing League (A2RL), which made its impressive debut this April at the Yas Marina Circuit, has announced the next phase of its challenge with the Drone Champions League (DCL), the world's premier professional drone racing organization. Building on the success of its inaugural event, the A2RL Drone Race continues to advance the frontiers of autonomous technology, merging human skill with innovative advancements in autonomous flight.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724188405/en/
The Abu Dhabi Autonomous Racing League (A2RL) x Drone Champions League (DCL) (Graphic: AETOSWire)
The Autonomous Drone Race will bring together teams from across the globe, welcoming established drone racing teams, research institutions and enthusiastic 'rookies.' All competitors will vie for a thrilling prize purse of US$1million, as they strive to achieve maximum agility and speed while successfully maneuvering through objects in the way. Registration is now open at a2rl.io, and interested teams are invited to apply for the competition. All entries will undergo a rigorous selection process to identify the successful competing teams. Those who pass the screening will be invited to participate in a series of tasks that will allow the judging panel to assess the teams' proficiency in using an open-source simulator to fly a drone autonomously. The grand finale will be held in April 2025, where the winner will be determined.
Organized by ASPIRE, A2RL integrates artificial intelligence (AI), autonomy and extreme sports to push the boundaries of future mobility and is spotlighted as the largest autonomous racing league in the world. The A2RL extreme autonomous drone race will see competing researchers program drones to navigate through a sequence of gates, avoiding obstacles, using onboard sensors and computational power. The main goal of the race is to set a benchmark for achieving maximum innovation in algorithms while using minimal sensor technology in complex environments.
As with all grand challenges, the A2RL Drone Challenge will also include a STEM focus and high-school students will be welcome to be a part of the competition.
Announcing the new competition, H.E. Faisal Al Bannai, Secretary General of ATRC, said: “It's only when you experiment in extreme conditions that you really discover new boundaries or breakthroughs in science. We’re inspiring global collaboration, driving technological progress, and creating a future where autonomous solutions transform industries and improve lives.”
Stephane Timpano, CEO at ASPIRE, said: “This is an exciting evolution of our A2RL extreme racing series. DCL is a like-minded partner with years of invaluable drone racing experience. Together, we are not only adding a new autonomous dimension to drone racing but are also demonstrating the limitless possibilities of unmanned aerial vehicles through this competition.”
Markus Stampfer, Executive Chair of Drone Champions AG, the organizer of the Drone Champions League (DCL), said: “At DCL, our mission has always been to push the boundaries of drone racing. Having successfully merged the worlds of virtual and physical drone racing, partnering with ASPIRE to advance autonomous drone flying is a natural next step for us. We are thrilled to bring our extensive experience and expertise to this pioneering competition, supporting ASPIRE with the knowledge we've gained from years of developing race drones and working with the world's best drone pilots.”
By advancing drone technology, this race aims to make drone usage accessible for all countries, ultimately reducing costs and driving innovation across industries such as health and logistics.
For media enquiries please contact: comms@a2rl.io or ATRC@edelman.com
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724188405/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
